Pharmaceutical Innovation for a Brighter Future”
RESEARCH & DEVELOPMENT: WE HAVE A PROVEN TRACK RECORD. DR. ASHLEYS PERFORMS STRONGLY IN THIS COMPLEX AREA OF R & D. THE COMPANY HAS A STRUCTURED ACCESS PLANNING FRAMEWORK IN PLACE AND HAS ACCESS PLANS FOR ALL LATE-STAGE CANDIDATES. DR. ASHLEYS LIMITED EXCELS IN R&D CAPACITY BUILDING.
ASHLEYS LIMITED HAS A STRONG R&D INFRASTRUCTURE AND A TEAM OF QUALIFIED PROFESSIONALS SUPPORTING R&D ACTIVITIES INCLUDING SYNTHESIS, ANALYTICAL, INTELLECTUAL PROPERTY AND DQA. AT OPTIMUS, EMPHASIS ON AN INNOVATIVE APPROACH IS THE KEY VALUE DRIVER FOR NEW PRODUCT DEVELOPMENT. DR. ASHLEYS LIMITED’S R&D CAPABILITIES OF INNOVATIVE PROCESS DEVELOPMENT, COST-EFFECTIVE TECHNOLOGY DEVELOPMENT AND STRONGHOLD ON CHIRAL CHEMISTRY HAVE HELPED US TO BECOME THE PARTNER OF CHOICE FOR MANY GLOBAL PLAYERS IN THE INDUSTRY.
AT THE SAME TIME, WE ARE INCORPORATING NEW MANUFACTURING TECHNOLOGIES, SUCH AS FLOW CHEMISTRIES AN INNOVATIVE EUROPEAN LABORATORY DEDICATED TO THE SYNTHESIS, MANUFACTURE, AND COMMERCIALIZATION OF ACTIVE PHARMACEUTICAL INGREDIENTS (APIS). DR. ASHLEYS LIMITED IS ABOVE ALL, A TRUSTED PARTNER. WE ARE FLEXIBLE, CUSTOMER-CENTRED, AND COMMITTED TO SUCCESSFUL LONG-TERM BUSINESS RELATIONSHIPS. OUR DEEP KNOWLEDGE OF INTERNATIONAL REGULATION HELPS YOU OVERCOME BARRIERS AND SPEED UP TIME-TO-MARKET PROCESSES. WE HAVE EXPERTISE IN REGISTERING APIS IN EUROPE, CANADA, TAIWAN, CHINA, RUSSIA, BRAZIL AND JAPAN, AMONG OTHERS.
WE ARE FULLY TRANSPARENT AND ACCOUNTABLE, SHARING THE RISKS OF EVERY PROJECT. THAT’S WHY THE REPUTATION OF OUR BRAND REACHES FAR BEYOND THE POINT OF DELIVERY.
MOREOVER, WE PROVIDE COMPREHENSIVE SUPPORT FOR ALL STAGES OF YOUR API DEVELOPMENT AND PRODUCTION – FROM PROCESS DEVELOPMENT AND OPTIMIZATION TO REGULATORY AFFAIRS. OUR HIGH-QUALITY APIS ARE PRODUCED IN ACCORDANCE WITH CGMP GUIDELINES AND ARE SUBJECT TO STRICT QUALITY ASSURANCE PROCEDURES.
- STERILE SAMPLING
- BIOBURDEN REDUCTION/PARTICULATE CONTROL
- STERILE FILTRATION
- PROCESS VALIDATION & EQUIPMENT QUALIFICATION
AT DR. ASHLEYS LIMITED, WE BELIEVE THAT R&D IS THE FOUNDATION FOR THE HARMONIOUS GROWTH OF ANY ORGANIZATION, AND WE VALUE RESEARCH & INNOVATION MORE THAN ANY OTHER ACTIVITY. THE R&D EXPERTISE HAS ENABLED US TO DEVELOP COMPLEX & NICHE PRODUCTS THAT GIVE US AN EDGE OVER THE COMPETITORS. OUR R&D IS WELL EQUIPPED WITH THE INFRASTRUCTURE THAT SUPPORTS ADVANCED RESEARCH AND INNOVATION, OUR TEAM CONTINUOUSLY THRIVES FOR THE DEVELOPMENT OF NDA AND PROCESS INNOVATION WITH THE APPROACH OF KNOWLEDGE-DRIVEN RESEARCH. DR. ASHLEYS R&D CENTRE HAS A STATE-OF-THE-ART FACILITY EQUIPPED WITH THE RIGHT INFRASTRUCTURE AND TECHNOLOGY WHICH ENABLES US TO EXECUTE R&D ACTIVITIES EFFECTIVELY & EFFICIENTLY. OPTIMUS R&D EFFORTS & ACTIVITIES ARE ALIGNED WITH ITS ORGANISATIONAL GOAL OF PROVIDING QUALITY PRODUCTS AT AFFORDABLE PRICES FOR THE PEOPLE IN NEED.
OUR INNOVATION IS STRATEGIC: WE ARE ON THE BRINK OF A REVOLUTION IN HUMAN HEALTHCARE, THE OPPORTUNITIES WILL BE IMMENSE. MANUFACTURERS OF ACTIVE PHARMACEUTICAL INGREDIENTS FOR PHARMA COMPANIES MUST MEET THE CHALLENGE.
ASHLEYS LIMITED’S FACILITIES ARE EQUIPPED WITH THE LATEST TECHNOLOGY TO GUARANTEE THE HIGHEST QUALITY PRODUCTION. WE HAVE AN R&D DEPARTMENT, A VERSATILE PILOT PLANT, AND A DIVERSE RANGE OF ANALYSIS AND REGULATORY SERVICES.API RESEARCH AND DEVELOPMENT WITH PURPOSE. GOOD MANUFACTURING PRACTICES ARE AT THE CORE OF DR. ASHLEYS LIMITED’S PHILOSOPHY. WE FOCUS CONSTANTLY ON IMPROVING OUR MOLECULAR SYNTHESIS PROCESSES, SHORTENING TIMES, AND IMPROVING THE FINAL QUALITY AND STABILITY OF THE MOLECULES.